Faruqi & Faruqi LLP is investigating potential claims against Nutex Health Inc. regarding securities issued between August 8, 2024, and August 15, 2025. Investors who suffered losses are encouraged to contact James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The deadline to seek the role of lead plaintiff is October 21, 2025.
Investors who suffered losses from Nutex Health Inc. (NASDAQ: NUTX) securities between August 8, 2024, and August 15, 2025, are encouraged to contact Faruqi & Faruqi, LLP. The firm is investigating potential claims against the company and has set a deadline of October 21, 2025, for investors to seek the role of lead plaintiff in a federal securities class action lawsuit [3].
The lawsuit alleges that Nutex Health Inc. violated federal securities laws by making false and/or misleading statements and/or failing to disclose key information. Specifically, the complaint alleges that Nutex engaged in a coordinated scheme with HaloMD to defraud insurance companies, resulting in unsustainable revenues. Additionally, the company overstated its ability to remediate material weaknesses in its internal controls over financial reporting and improperly calculated stock-based compensation obligations [1][2][3].
Investors who purchased or acquired Nutex securities during the specified period are urged to contact Faruqi & Faruqi partner James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The firm has a proven track record of recovering hundreds of millions of dollars for investors since its founding in 1995.
References:
[1] https://www.prnewswire.com/news-releases/nutex-health-nutx-securities-suit-alleges-fraud-and-financial-misstatements---hagens-berman-302538433.html
[2] https://www.morningstar.com/news/business-wire/20250825464928/nutx-investors-have-opportunity-to-lead-nutex-health-inc-securities-fraud-lawsuit-with-the-schall-law-firm
[3] https://www.marketscreener.com/news/investor-deadline-approaching-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-nu-ce7c50dede89f726
Comments
No comments yet